Oncolytics Biotech (NASDAQ:ONCY) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Oncolytics Biotech (NASDAQ:ONCY) in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has a $5.00 target price on the stock.

Oncolytics Biotech Stock Performance

Shares of NASDAQ ONCY opened at $0.92 on Thursday. The stock has a fifty day moving average of $0.99 and a 200-day moving average of $1.04. The stock has a market cap of $71.18 million, a PE ratio of -3.08 and a beta of 1.80. Oncolytics Biotech has a fifty-two week low of $0.85 and a fifty-two week high of $2.30.

Oncolytics Biotech (NASDAQ:ONCY) last posted its earnings results on Thursday, August 1st. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. During the same period in the previous year, the business posted ($0.09) EPS. On average, sell-side analysts predict that Oncolytics Biotech will post -0.29 EPS for the current year.

Institutional Trading of Oncolytics Biotech

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC purchased a new stake in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) in the first quarter, according to its most recent 13F filing with the SEC. The fund purchased 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 0.07% of Oncolytics Biotech at the end of the most recent reporting period. 6.82% of the stock is owned by institutional investors and hedge funds.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.